Zynlonta 10 mg powder for concentrate for solution for infusion
Sponsors
ADC Therapeutics S.A., Universitaet Muenster, The University Of Birmingham, Humanitas Mirasole S.p.A.
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL)Diffuse large B-cell lymphoma (DLBCL)Follicular lymphoma (FL) grade 3BHigh-grade B-cell lymphoma (HGBL)Patients affected by relapsed/refractory DLBCL or HGBCL failing CAR T-cell therapyRelapsed and refractory mature B-cell non-Hodgkin Lymphoma
Phase 2
Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) who have progressive disease after CAR T-cell treatment - LORELY
RecruitingCTIS2024-516929-31-00
Start: 2023-06-19Target: 50Updated: 2026-01-16
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
WithdrawnCTIS2023-509861-19-00
Target: 104Updated: 2025-04-24
Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Not yet recruitingCTIS2024-510575-38-00
Target: 23Updated: 2025-08-18
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
RecruitingCTIS2023-509861-19-01
Start: 2025-09-30Target: 104Updated: 2025-12-29